Review | Published:

Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis

European Journal of Clinical Nutrition volume 71, pages 683693 (2017) | Download Citation

Abstract

The objective of this study was to assess whether vitamin D (VD) treatment alters the overall all-cause and cardiovascular mortalities in a chronic kidney disease (CKD) population. We systematically searched PubMed, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials without language restriction, until the publication date of 22 February 2016. All related literatures that compared VD treatment with non-VD treatment and reported the mortality of patients with CKD (including those undergoing dialysis) were identified. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated by using the random- and fixed-effects models. Randomised controlled trials (RCTs) that used the intention-to-treat principle and observational studies (OSs) were analysed separately. For this study, 38 studies involving 223 429 patients (17 RCTs, n=1819 and 21 OSs, n=221610) were included. In the OSs, VD treatment was significantly associated with reductions in both all-cause and cardiovascular mortalities; however, such significant association was not found in the RCTs. The existing RCTs do not provide sufficient or precise evidence that VD supplementation affects the mortality of patients with CKD, although subsets of patients that could potentially benefit from VD treatment can be identified by using the existing data from the RCTs. Nevertheless, large-size RCTs are needed in the future to assess any potential differences in survival prospectively.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , . Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease. Dis Markers 2015; 2015: 868961.

  2. 2.

    , , , . Vitamin D and clinical outcomes in dialysis. Semin Dial 2015; 28: 604–609.

  3. 3.

    . Vascular calcification - pathological mechanism and clinical application -. the effect of phosphate binders on vascular calcification. Clin Calcium 2015; 25: 711–721.

  4. 4.

    , . The association of chronic kidney disease-mineral bone disorder and cardiovascular risk. J Ren Care 2010; 36 (Suppl 1), 61–67.

  5. 5.

    , , , , , et al. Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study. Lancet Diabetes Endocrinol 2014; 2: 719–729.

  6. 6.

    , , , , , . Vitamin D supplementation in the treatment of chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol 2016; 39: 56–61.

  7. 7.

    , , , , , . Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J 2015; 8: 41–48.

  8. 8.

    , , , , , et al. Vitamin D deficiency in dialysis patients: effect of dialysis modality and implications on outcome. J Ren Nutr 2010; 20: 359–367.

  9. 9.

    , , , , , et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2011; 26: 1024–1032.

  10. 10.

    , , , , , et al. Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 2012; 60: 567–575.

  11. 11.

    , , , , . Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 2013; 14: 199.

  12. 12.

    , , , , , . Vitamin D status and mortality of German hemodialysis patients. Anticancer Res 2012; 32: 391–395.

  13. 13.

    , , , , , et al. Vitamin D deficiency aggravates nephrotoxicity, hypertension and dyslipidemia caused by tenofovir: role of oxidative stress and renin-angiotensin system. PLoS One 2014; 9: e103055.

  14. 14.

    , , , . Immune response modulation by vitamin D: role in systemic lupus erythematosus. Front Immunol 2015; 6: 513.

  15. 15.

    , , , , , et al. Vitamin D and immune function in chronic kidney disease. Clin Chim Acta 2015; 450: 135–144.

  16. 16.

    , . Vitamin D and inflammatory diseases. J Inflamm Res 2014; 7: 69–87.

  17. 17.

    , , , , , . A systematic review protocol examining the effect of vitamin D supplementation on endothelial function. BMJ Open 2015; 5: e006835.

  18. 18.

    . Vitamin D-mediated apoptosis in cancer and obesity. Horm Mol Biol Clin Investig 2014; 20: 43–49.

  19. 19.

    , , , , , et al. Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial. PLoS One 2014; 9: e109998.

  20. 20.

    , , , , , et al. Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrol 2015; 16: 11.

  21. 21.

    , , , , , et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ 2016; 352: i1102.

  22. 22.

    , , , . Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies. Chest 2015; 147: 335–346.

  23. 23.

    , , , , , et al. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) 1981; 282: 1919–1924.

  24. 24.

    , , , , , et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358–363.

  25. 25.

    , , , , , et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36: 550–561.

  26. 26.

    , , , , , et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004; 43: 877–890.

  27. 27.

    , , , , , et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263–276.

  28. 28.

    , , , , , et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543–1551.

  29. 29.

    , , , , , et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523–3531.

  30. 30.

    , , , , , et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012; 96: 672–679.

  31. 31.

    , , , . Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 1143–1149.

  32. 32.

    , , , , , et al. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol Dial Transplant 2013; 28: 1779–1786.

  33. 33.

    , , , , , et al. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Am J Kidney Dis 2014; 64: 696–705.

  34. 34.

    , , , , , et al. Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: a randomized, double-blind, placebo-controlled pilot study. J Vasc Access 2014; 15: 88–94.

  35. 35.

    , , , , , et al. Nutritional vitamin D supplementation in dialysis: a randomized trial. Clin J Am Soc Nephrol 2015; 10: 611–619.

  36. 36.

    , , , , , et al. Effects of a single, high oral dose of 25-hydroxycholecalciferol on the mineral metabolism markers in hemodialysis patients. Ther Apher Dial 2015; 19: 212–219.

  37. 37.

    , , , , , et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674–684.

  38. 38.

    , , , , , et al. Effect of paricalcitol on left ventricular mass and function in CKD–the OPERA trial. J Am Soc Nephrol 2014; 25: 175–186.

  39. 39.

    , , , , , et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179–184.

  40. 40.

    , , , , , et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115–1125.

  41. 41.

    , , , , , et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351–357.

  42. 42.

    , , , , , et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771–780.

  43. 43.

    , , , , . Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613–1619.

  44. 44.

    , , , , , et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070–1078.

  45. 45.

    , , , . Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397–403.

  46. 46.

    , , , , , et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008; 19: 1379–1388.

  47. 47.

    , , , , , et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963–972.

  48. 48.

    , , , , , et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 2010; 14: 43–50.

  49. 49.

    , , , , , et al. Patient survival and the combination of vitamin D and phosphorus binder in dialysis. Dial Transplant 2010; 39: 427–431.

  50. 50.

    , , , , , et al. Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Nephron Clin Pract 2011; 118: c204–c210.

  51. 51.

    , , , , , et al. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood Purif 2011; 32: 124–132.

  52. 52.

    , , , , , et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH?? 150pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012; 27: 3588–3594.

  53. 53.

    , , , , , . Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients. Clin Exp Nephrol 2012; 16: 779–785.

  54. 54.

    , , , , . Effect of alfacalcidol therapy on the survival of chronic hemodialysis patients. Ther Apher Dial 2012; 16: 248–253.

  55. 55.

    , , , , , et al. Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS One 2013; 8: e67836.

  56. 56.

    , , , , . Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am J Ther 2013; 20: 480–486.

  57. 57.

    , , , . Oral active vitamin d treatment and mortality in maintenance hemodialysis patients. Cardiorenal Med 2014; 4: 217–224.

  58. 58.

    , , , , . Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients. Ther Apher Dial 2015; 19: 235–244.

Download references

Author information

Affiliations

  1. Department of Pharmacy, The Third People’s Hospital of Changzhou, Changzhou, People’s Republic of China

    • R J Lu
    • , S M Zhu
    • , F L Tang
    •  & Z D Fan
  2. Department of Urinary Surgery, The Third People's Hospital of Changzhou, Changzhou, People’s Republic of China

    • X S Zhu
    • , G L Wang
    •  & Y F Jiang
  3. Department of Internal Medicine, The Third People's Hospital of Changzhou, Changzhou, People’s Republic of China

    • Y Zhang

Authors

  1. Search for R J Lu in:

  2. Search for S M Zhu in:

  3. Search for F L Tang in:

  4. Search for X S Zhu in:

  5. Search for Z D Fan in:

  6. Search for G L Wang in:

  7. Search for Y F Jiang in:

  8. Search for Y Zhang in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to Y Zhang.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/ejcn.2017.59

Further reading